Pipeline

Constantly growing pipeline of product opportunities

EVT Innovate develops drug discovery programmes and assets, both internally or through academic collaborations. Evotec seeks to partner these into collaborations in return for upfront payments, ongoing research payments and significant financial upside through milestones and royalties.

Pipeline of product opportunities (including EVT Execute programmes)

Programme
Therapeutic area/Indication
Partner
Status
EVT201
CNS - Insomnia
Jingxin
Phase II
EVT401
Immunology & Inflammation
CONBA Group
Phase I
ND
Women`s health - Endometriosis
Bayer
Phase I
ND
Women`s health - Endometriosis
Bayer
Phase I
ND
Women`s health - Endometriosis
Bayer
Phase I
SGM-1019
Inflammation/Pain
Second Genome
Phase I
CT7001
Oncology
Carrick
Phase I
ND
Respiratory
Boehringer Ingelheim
Phase I
ND
Chronic cough
Bayer
Phase I
Various
Women`s health - Endometriosis
Bayer
Pre-clinical
ND
Immunology & Inflammation
Topas Therapeutics
Pre-clinical
EVT801
Oncology
Sanofi
Pre-clinical
EVT701
Oncology
Sanofi
Pre-clinical
Various
Nephrology
Bayer
Discovery
Various
Neurodegeneration
Celgene
Discovery
Various
Immunology & Inflammation - Tissue Fibrosis
Pfizer
Discovery
Various
Metabolic - Diabetes
Sanofi
Discovery
TargetImmuniT
Oncology - Immunotherapy
Sanofi/Apeiron
Discovery
Various
Antiviral
Haplogen
Discovery
Various
Nephrology
AstraZeneca
Discovery
Various
Oncology
Exscientia
Discovery
ND
Anti-infectives
Forge Therapeutics
Discovery
ND
FSHD
Facio Therapies
Discovery
Various
Oncology
Carrick
Discovery
INDY inhibitor
Metabolic
Eternygen
Discovery
Various
Fibrotic disease
Fibrocor
Discovery
Various
Various
Lab282/Lab150
Discovery
Various
Internal: Oncology, CNS, Metabolic, Pain & Inflammtion, Immunology and Anti-invectives
>30 further programmes
Discovery
Programme EVT201
Therapeutic area/Indication CNS - Insomnia
Partner Jingxin
Status Phase II
Programme EVT401
Therapeutic area/Indication Immunology & Inflammation
Partner CONBA Group
Status Phase I
Programme ND
Therapeutic area/Indication Women`s health - Endometriosis
Partner Bayer
Status Phase I
Programme ND
Therapeutic area/Indication Women`s health - Endometriosis
Partner Bayer
Status Phase I
Programme ND
Therapeutic area/Indication Women`s health - Endometriosis
Partner Bayer
Status Phase I
Programme SGM-1019
Therapeutic area/Indication Inflammation/Pain
Partner Second Genome
Status Phase I
Programme CT7001
Therapeutic area/Indication Oncology
Partner Carrick
Status Phase I
Programme ND
Therapeutic area/Indication Respiratory
Partner Boehringer Ingelheim
Status Phase I
Programme ND
Therapeutic area/Indication Chronic cough
Partner Bayer
Status Phase I
Programme Various
Therapeutic area/Indication Women`s health - Endometriosis
Partner Bayer
Status Pre-clinical
Programme ND
Therapeutic area/Indication Immunology & Inflammation
Partner Topas Therapeutics
Status Pre-clinical
Programme EVT801
Therapeutic area/Indication Oncology
Partner Sanofi
Status Pre-clinical
Programme EVT701
Therapeutic area/Indication Oncology
Partner Sanofi
Status Pre-clinical
Programme Various
Therapeutic area/Indication Nephrology
Partner Bayer
Status Discovery
Programme Various
Therapeutic area/Indication Neurodegeneration
Partner Celgene
Status Discovery
Programme Various
Therapeutic area/Indication Immunology & Inflammation - Tissue Fibrosis
Partner Pfizer
Status Discovery
Programme Various
Therapeutic area/Indication Metabolic - Diabetes
Partner Sanofi
Status Discovery
Programme TargetImmuniT
Therapeutic area/Indication Oncology - Immunotherapy
Partner Sanofi/Apeiron
Status Discovery
Programme Various
Therapeutic area/Indication Antiviral
Partner Haplogen
Status Discovery
Programme Various
Therapeutic area/Indication Nephrology
Partner AstraZeneca
Status Discovery
Programme Various
Therapeutic area/Indication Oncology
Partner Exscientia
Status Discovery
Programme ND
Therapeutic area/Indication Anti-infectives
Partner Forge Therapeutics
Status Discovery
Programme ND
Therapeutic area/Indication FSHD
Partner Facio Therapies
Status Discovery
Programme Various
Therapeutic area/Indication Oncology
Partner Carrick
Status Discovery
Programme INDY inhibitor
Therapeutic area/Indication Metabolic
Partner Eternygen
Status Discovery
Programme Various
Therapeutic area/Indication Fibrotic disease
Partner Fibrocor
Status Discovery
Programme Various
Therapeutic area/Indication Various
Partner Lab282/Lab150
Status Discovery
Programme Various
Therapeutic area/Indication Internal: Oncology, CNS, Metabolic, Pain & Inflammtion, Immunology and Anti-invectives
Partner >30 further programmes
Status Discovery

Contact us

Evotec

Business Development

T +44.(0)1235.86 15 61 F +44.(0)1235.86 31 39 vCard
TOP